US equities |
GOOGL $283.31 ▼-12.80% GOOG $281.65 ▼-12.50% MSFT $530.38 ▼-0.12% META $624.82 ▲+2.01% MU $934.43 ▼-4.96% AMZN $243.77 ▼-4.25% NVDA $213.46 ▼-0.89% AAPL $348.92 ▲+1.48%
FinancialContent

HOOKIPA Pharma Inc. - Common Stock (NQ:HOOK)

0.8403 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HOOKIPA Pharma Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch ↗
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
Via InvestorPlace
News headline image
HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024 ↗
HOOK stock results show that HOOKIPA Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views ↗
 
Via Benzinga
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
Via AB Newswire
Topics Artificial Intelligence
News headline image
HOOKIPA Pharma: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday? ↗
HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving... 
Via Benzinga
News headline image
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients ↗
Roche study results show prolonged survival in R/R diffuse large B-cell lymphoma patients treated with Columvi (glofitamab) + GemOx vs. Rituxan + GemOx. 
Via Benzinga
News headline image
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023 ↗
HOOK stock results show that HOOKIPA Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month ↗
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal ↗
HOOKIPA Pharma's strategic focus on HB-200 program for HPV16+ HNSCC, infectious disease cure collaboration with Gilead, and recent developments. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades' ↗
On CNBC’s "Halftime Report Final Trades," Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. 
Via Benzinga
News headline image
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
News headline image
Nasdaq Gains 100 Points; CarMax Earnings Top Views ↗
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Thursday. The Dow traded up 0.37% to 37,218.15 while the NASDAQ rose 0.73% to 14,885.76.... 
Via Benzinga
Topics Stocks
News headline image
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Crude Oil Moves Lower; Micron Issues Strong Forecast ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.58% to 37,296.40 while the NASDAQ rose 0.77% to 14,891.87. The... 
Via Benzinga
Topics Stocks
News headline image
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today? ↗
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million,  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >